Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 1_suppl, 2009, Pages 09S-16S

  Stangier, Joachim ^a   Clemens, Andreas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

dabigatran; dabigatran etexilate; direct thrombin inhibitor; pharmacodynamics; pharmacokinetics

Indexed keywords

AMIODARONE; DABIGATRAN; DABIGATRAN ETEXILATE; QUINIDINE; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; THROMBIN;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ELIMINATION HALF-LIFE; HIP ARTHROPLASTY; HUMAN; KIDNEY FUNCTION; MAXIMUM DRUG EFFECT; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; THROMBIN TIME; THROMBOEMBOLISM; TOTAL KNEE ARTHROPLASTY; VOLUME OF DISTRIBUTION; BLOOD; BLOOD CLOTTING; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFECT; DRUG INTERACTION; EVIDENCE BASED MEDICINE; KNEE ARTHROPLASTY; ORAL DRUG ADMINISTRATION; REVIEW; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BLOOD COAGULATION; DRUG APPROVAL; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; PYRIDINES; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 77952167209     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029609343004     Document Type: Article

References (35)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
2. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028-1040.
3. Husmann M, Barton M. Therapeutical potential of direct thrombin inhibitors for atherosclerotic vascular disease. Expert Opin Investig Drugs. 2007;16(5):563-567.
4. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res. 1999;93(5): 203-241.
5. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109(suppl 1):S9-S15.
6. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Invitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98(1): 155-162.
7. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186-195.
8. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45(9): 1757-1766.
9. van Ryn J, Hauel N, Waldmann L, Wienen W. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood (ASH Annual Meeting Abstracts) 2007 Nov 16; 110 (11). http://abstracts.hematologylibrary.org/content/vol110/issue11/. Accessed March 12, 2009.
10. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
11. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost. 2007;98(2):333-338.
12. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2): 386-399.
13. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005; 45(5): 555-563.
14. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1): 47-59.
15. Eriksson BI, Dahl OE, Buller HR, et al, for the BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103-111.
16. European Medicines Agency (EMEA). European Public Assessment Report-Pradaxa. EMEA web site [online]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-PI-en.pdf.Accessed March 12, 2009.
17. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295.
18. Troconiz IF, Tillmann C, Liesenfeld KH, Schäfer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol. 2007;47(3): 371-382.
19. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2(9): 1573-1580.
20. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62(5):527-537.
21. Stangier J, Nehmiz G, Reilly P, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran in a dose finding trial in atrial fibrillation [abstract no. OR271]. XXth Congress of the International Society of Thrombosis and Haemostasis; 2005 Aug 6-12; Sydney. http://www.blackwellpublishing.com/isth2005/abstract.asp?id=47339. Accessed March 12, 2009.
22. Garnett C, Liesenfeld KH, Tillmann C. Modelling and clinical trial simulation in drug development: the effect of renal impairment on the exposure-response relationship of a direct thrombin inhibitor, BIBR 1048, in hip replacement replacement [poster]. Annual Meeting of the American Association of Pharmaceutical Scientists; 2003 Nov, Salt Lake City (UT). Abstract 2008.
23. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411-1419.
24. Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract no. P-T-677]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva. http://www.blackwellpublishing.com/isth2007/abstract.asp?id=67231. Accessed March 12, 2009.
25. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9(1):59-68.
26. Stangier J, Stähle H, Rathgen K, et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract no. P-W-672]. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva. http://www.blackwellpublishing.com/isth2007/abstract.asp?id=67922. Accessed March 12, 2009.
27. Carlsson SC, Mattsson C, Eriksson UG, et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res. 2005; 115(1-2):9-18.
28. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, and, and American College of Chest Physicians Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl): 141S-159S.
29. van Ryn J, Ruehl D, Priepke H, et al. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370). 13th Congress of the European Hematology Association, June 12-15, 2008. Haematologica. 2008;93(suppl 1):148.
30. Eriksson BI, Dahl OE, Rosencher N, et al, for the RENOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949-956.
31. Eriksson BI, Dahl OE, Rosencher N, et al, and the REMODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-2185.
32. Ginsberg JS, Davidson BL, Comp PC, et al, for the RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1):1-9.
33. Schulman S, Reilly PA. Dabigatran etexilate: future directions in anticoagulant treatment. Clin Appl Thromb Hemost. 2009; in press.
34. Dahl OE. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement: Rationale for dose regimen. Clin Appl Thromb Hemost. 2009; In press.
35. Eriksson BI, Friedman RJ. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009; In press.